cancer

The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Flag link:
Cancer patients know immuno-oncology and top drugs, but lack details: study
Cancer patients know immuno-oncology and top drugs, but lack details: study
Fierce Pharma
patients
cancer
immuno-oncology
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Flag link:
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Motley Fool
Big Pharma
viral hepatitis
respiratory disease
autoimmune disease
cardiovascular disease
pain
diabetes
cancer
Flag link:
WHO to Launch Pilot to Prequalify Biosimilars
WHO to Launch Pilot to Prequalify Biosimilars
RAPS.org
WHO
biosimilars
cancer
Flag link:
Daiichi Sankyo hands off cancer drug to Boston Pharma
Daiichi Sankyo hands off cancer drug to Boston Pharma
BioPharma Dive
Boston Pharmaceuticals
Daiichi Sankyo
DS-5010
cancer
Flag link:
Nanotech, immunotherapy combo vaccinates mouse against cancer
Nanotech, immunotherapy combo vaccinates mouse against cancer
Drug Delivery Business News
nanotech
immunotherapy
vaccines
cancer
Flag link:
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
Endpoints
FDA
drug approvals
cancer
oncology
Flag link:
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
NY Times, NY
cancer
oncology
clinical trials
patients
Flag link:
Ending the era of $100,000 cancer drugs
Ending the era of $100,000 cancer drugs
Pharmafile
cancer
drug pricing
oncology
Flag link:
Making the Promise of Immunotherapeutics into Reality
Making the Promise of Immunotherapeutics into Reality
Elsevier
immunotherapy
cancer
Flag link:
GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research
GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research
Endpoints
GSK
reorganization
Emma Walmsley
Pharma CEOs
R&D
cancer
Flag link:
The Startling History Behind Merck's New Cancer Blockbuster
The Startling History Behind Merck's New Cancer Blockbuster
Forbes
Merck
Keytruda
cancer
R&D
Organon
Flag link:
King cancer: The top 10 therapeutic areas in biopharma R&D
King cancer: The top 10 therapeutic areas in biopharma R&D
Endpoints
R&D
cancer
neurology
infection
immunology
cardiovascular disease
diabetes
Flag link:
The Fastest Growing Cancer Company You've Never Heard Of
The Fastest Growing Cancer Company You've Never Heard Of
Motley Fool
devices
Novocure
tumor treating fields
cancer
TTFields
glioblastoma
ovarian cancer
pancreatic cancer
lung cancer
Flag link:
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Flag link:
How Reproducible are Preclinical Study Results?
How Reproducible are Preclinical Study Results?
Xtalks
preclinical study results
cancer
oncology
clinical trials
Flag link:
Marketing cancer drugs is costly, but pharma has room for savings: report
Marketing cancer drugs is costly, but pharma has room for savings: report
Fierce Pharma
pharma marketing
cancer
Flag link:
Personalized cancer vaccines vanquish melanoma in small but encouraging study
Personalized cancer vaccines vanquish melanoma in small but encouraging study
Stat
personalized medicine
cancer
vaccines
melanoma
Keytruda
Merck
Neon Therapeutics
Flag link:
Two cancer drug prices have already been hiked by 8% this year
Two cancer drug prices have already been hiked by 8% this year
Marketwatch
drug pricing
cancer
Amgen
Blincyto
Teva Pharmaceutical
Treanda
lymphoma
leukemia
Flag link:
Vivace Therapeutics Comes Out of Stealth With $25M for Cancer Drugs
Vivace Therapeutics Comes Out of Stealth With $25M for Cancer Drugs
Xconomy
Vivace Therapeutics
cancer
Flag link: